Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

FDA Approved Altuzan and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer

FDA Approved Altuzan and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer

Approved by the FDA on 14 November 2014, Altuzan began being used with drugs such as paclitaxel and topotecan for platinum (cisplatin, carboplatin)-resistant recurrent ovarian, fallopian tube (ovarian tube) or peritoneal (abdominal lining) cancers. The fallopian tube lies between the uterus and ovaries. Altuzan works by preventing formation of new blood vessels feeding the tumor.

Previously proven effective in several cancers (colorectal, brain, cervical), Altuzan thus became part of ovarian, fallopian tube and peritoneal cancer treatment. Its most common side effects are high blood pressure, decreased neutrophils, a type of blood cell, and nervous system damage.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

FDA Approved Altuzan and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy